Recombinant human microplasmin: production and potential therapeutic properties. - Wikidata - wikimedia - TriplyDB

Recombinant human microplasmin: production and potential therapeutic properties.

Recombinant human microplasmin: production and potential therapeutic properties.

http://www.wikidata.org/entity/Q44518906

about

Differential vitreous dye diffusion following microplasmin or plasmin pre-treatment.Molecular biology of pharmacologic vitreolysis.High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris.Alteplase for acute ischemic stroke.Enzyme-induced posterior vitreous detachment in the rat produces increased lens nuclear pO2 levels.Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.Does plasmin have anticoagulant activity?Plant-made pharmaceuticals: leading products and production platforms.Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin.Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review Serine-proteases as plasminogen activators in terms of fibrinolysis.Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice.Enzymes approved for human therapy: indications, mechanisms and adverse effects.The evolution of recombinant thrombolytics: Current status and future directions Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes.Production of recombinant human microplasminogen and pilot study in inducing posterior vitreous detachment.Release of experimental retinal vein occlusions by direct intraluminal injection of ocriplasmin.Purification and characterization of mutant miniPlasmin for thrombolytic therapy.Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels.Effects of microplasmin on recovery in a rat embolic stroke model.Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator.

P2860

Q33550517-5A43233C-7095-4E5E-B859-7843EE92C0E6 Q34565447-BF1DE345-F407-4F4F-82C7-51F7CB41DA0D Q35657072-7DFAB2BE-871F-425F-878B-EFA6D4EDE462 Q36484897-47AAAAD8-954E-406F-994B-1F2AC48E9E17 Q37222058-F8B71848-9439-4260-BA60-D3AF43C879E7 Q37640163-972E5A0F-AFB1-41C2-9BB2-58D21BDAE443 Q37734885-DD46822E-8BA4-407D-A38E-2D3ADEE047DC Q37859060-B2460144-FAC8-4B03-B065-E1AFE9106B86 Q37903963-7F76A916-2B33-426B-B3B2-63D0E0410843 Q37925601-73239913-4635-404C-95D3-B2721B1CFA94 Q38024834-8CFB62AE-2C9B-4223-BE3A-90D9E8571CDF Q38300477-BE438319-3196-4B38-93F6-F884CF5DD12A Q38342838-C1A7FA36-EBC2-4500-8818-129A2AD4BF34 Q38803641-14236C4B-A678-411C-9788-EE1C63B51D8C Q39960008-84943C10-510F-453C-A1D8-4B128A176AC0 Q40357799-4101DBC1-2D0A-409C-88DD-AAAEFB9A91DA Q41949426-F39A4421-7BB7-4CA4-8ED9-4509D0793EE9 Q43072712-EED33230-C105-42B2-9468-032260B91567 Q43104744-7E6DC531-CE62-441D-9B21-E35B2532CBBA Q48127802-4900BD35-657A-41EF-8382-30F2F4CE8156 Q48834243-C66DC127-BA63-4A75-9CA6-9FA2BC87FDD7 Q51741540-D263DEF6-B4EA-45BB-9399-1F0F5D201067

P2860

Recombinant human microplasmin: production and potential therapeutic properties.

http://www.wikidata.org/entity/Q44518906

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Recombinant human microplasmin: production and potential therapeutic properties.

@en

Recombinant human microplasmin: production and potential therapeutic properties.

@nl

type

label

Recombinant human microplasmin: production and potential therapeutic properties.

@en

Recombinant human microplasmin: production and potential therapeutic properties.

@nl

prefLabel

Recombinant human microplasmin: production and potential therapeutic properties.

@en

Recombinant human microplasmin: production and potential therapeutic properties.

@nl

P1433

Q44518906-C83C0F40-27A1-4615-9D27-58F8CB64FD0F

P1476

Q44518906-D402041D-EAF4-4D50-9AA2-2F329508B905

P2093

Q44518906-1846280F-E5EB-469E-8AA0-F49DC4C4CF08

Q44518906-2C041BF0-C1F4-4180-989C-E528F017B5BF

Q44518906-39612ED1-F5BA-4F20-AEA3-F3A0447B9558

Q44518906-7E7EFF04-606D-45D1-9178-73C24AAF05C8

Q44518906-B2F442E1-CFA3-487F-9802-AD8F3C891060

Q44518906-B60F4C64-0F2A-491C-8E2E-121876B7BBF1

Q44518906-FA8705B7-0A81-4483-A56D-AC0C82F220DA

P2860

Q44518906-0F2FE3DA-80E0-4F35-8CAA-4DEFEBC81611

Q44518906-19781979-5E44-4F14-96CD-D2136656AE46

Q44518906-2E874A91-1764-46E7-9DD4-9B808C363A41

Q44518906-547955BC-A9D1-4EC3-9BC0-CE9AD6AE3E91

Q44518906-6EFBFB18-D21C-4551-B4D6-21ACAB40B2CA

Q44518906-AE645A23-4767-4A9A-9BD6-6A753C534008

Q44518906-D990A42F-BE69-4AF6-93FA-079EBE0AD0F3

P304

Q44518906-864451AB-3C9D-4D09-A3AB-41A761D0060D

P31

Q44518906-85A2BCA1-14B7-4462-A86A-89B0B4F16E67

P356

Q44518906-8BA5A47B-4724-484C-817B-DF1D7FAEC9F9

P433

Q44518906-E47C9A5A-E561-460B-92FC-2AAEDCA0F404

P478

Q44518906-42460B0C-7C81-4ED7-92F9-714D1A902C42

P577

Q44518906-B63F67AF-D274-4A3F-BC9A-27D4E7FBD8D6

P5875

Q44518906-3877D620-0665-474C-9EBD-0A5820189F0A

P698

Q44518906-4239616D-9475-41AD-A788-DE5BB14E0AB9

P356

J.1538-7836.2003.00078.X

P1433

Journal of Thrombosis and Haemostasis

P1476

Recombinant human microplasmin: production and potential therapeutic properties.

@en

P2093

B Van Hoef

http://www.w3.org/2001/XMLSchema#string

D Cingolani

http://www.w3.org/2001/XMLSchema#string

D Collen

http://www.w3.org/2001/XMLSchema#string

E Demarsin

http://www.w3.org/2001/XMLSchema#string

N Nagai

http://www.w3.org/2001/XMLSchema#string

S Wouters

http://www.w3.org/2001/XMLSchema#string

Y Laroche

http://www.w3.org/2001/XMLSchema#string

P2860

The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

Molecular cloning and characterization of a full-length cDNA clone for human plasminogen.

Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.

Inhibition of clot-bound alpha 2-antiplasmin enhances in vivo thrombolysis.

Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.

Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.

Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.

P304

307-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1538-7836.2003.00078.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10652236

http://www.w3.org/2001/XMLSchema#string

P698

12871505

http://www.w3.org/2001/XMLSchema#string